4-氯吡啶 | 626-61-9

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-氯吡啶
• 中文别名: 4-氯基吡啶
• 英文名称: 4-Chloropyridine
• CAS: 626-61-9
• 化学式: C₅H₄ClN
• mdl: MFCD00044570
• 分子量: 113.546
• InChiKey: PVMNPAUTCMBOMO-UHFFFAOYSA-N

物化性质

• 熔点：
  -43.5°C
• 沸点：
  147℃
• 密度：
  1.200
• 闪点：
  53℃
• 颜色/状态：
  Liquid
• 溶解度：
  In water, 8.54 mg/L at 25 °C (est)
• 蒸汽压力：
  4.5 mm Hg at 25 °C (est)
• 解离常数：
  pKa = 3.84 (conjugate acid)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

ADMET

毒理性

• 毒性总结

识别和使用：4-氯吡啶是一种液体。人类研究：无数据可用。动物研究：无数据可用。生态毒性研究：以316毫克/千克的剂量单次口服给予成年雄性鹌鹑（Coturnix coturnix）4-氯吡啶。它没有使雌性伴侣产生的蛋的生育能力降低超过50%。

IDENTIFICATION AND USE: 4-Chloropyridine is a liquid. HUMAN STUDIES: There are no data available. ANIMAL STUDIES: There are no data available. ECOTOXICITY STUDIES: 4-Chloropyridine was administered at 316 mg/kg as single oral dose to adult male Coturnix quail (Coturnix coturnix). It did not reduce the fertility of eggs produced by female mates by more than 50%.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 相互作用

氯化钴(II)（CoCl2）本身不具有诱变性，但在4-取代吡啶存在的情况下，对鼠伤寒沙门氏菌的测试株进行了诱变活性的测试。当与吡啶、甲基异烟酸、4-甲基吡啶、4-乙基吡啶、4-氯吡啶或4-溴吡啶结合时，CoCl2在TA1537和TA2637菌株中表现出诱变性。CoCl2与异烟酸、4-氰基吡啶、4-氨基吡啶或4-二甲氨基吡啶的混合物没有表现出诱变性。从光谱观察来看，这种联合诱变性可能是由于这些化合物与Co(II)阳离子形成中等至弱强度的配合物所致。

Cobalt(II) chloride (CoCl2), non-mutagenic by itself, has been tested for mutagenic activity in the presence of 4-substituted pyridines in the test strains of Salmonella typhimurium. CoCl2 was found to be mutagenic in strains TA1537 and TA2637, when combined with pyridine, methyl isonicotinate, 4-methyl-pyridine, 4-ethylpyridine, 4-chloropyridine or 4-bromopyridine. Mixtures of CoCl2 and isonicotinic acid, 4-cyanopyridine, 4-aminopyridine, or 4-dimethylaminopyridine exhibited no mutagenicity. Judging from the spectral observations, such combined mutagenicity may be due to the formation of moderate to weak complexes between these compounds and the Co(II) cation.

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 立即急救：确保已经进行了充分去污。如果患者停止呼吸，开始人工呼吸，最好使用需求阀复苏器、气囊面罩装置或口袋面罩，按培训操作。如有必要，执行心肺复苏。立即用缓慢流动的水冲洗受污染的眼睛。不要催吐。如果发生呕吐，让患者向前倾或放在左侧（如果可能的话，头部向下）以保持呼吸道畅通，防止吸入。保持患者安静，维持正常体温。寻求医疗帮助。 /毒物A和B/

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 基本治疗：建立专利气道（如有需要，使用口咽或鼻咽气道）。如有必要，进行吸痰。观察呼吸不足的迹象，如有需要，辅助通气。通过非循环呼吸面罩以10至15升/分钟的速度给予氧气。监测肺水肿，如有必要，进行治疗……。监测休克，如有必要，进行治疗……。预防癫痫发作，如有必要，进行治疗……。对于眼睛污染，立即用水冲洗眼睛。在运输过程中，用0.9%的生理盐水（NS）持续冲洗每只眼睛……。不要使用催吐剂。对于摄入，如果患者能吞咽、有强烈的干呕反射且不流口水，则用温水冲洗口腔，并给予5毫升/千克，最多200毫升的水进行稀释……。在去污后，用干燥的无菌敷料覆盖皮肤烧伤……。/毒药A和B/

/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

毒理性

• 解毒与急救

/SRP:/ 高级治疗：对于昏迷、严重肺水肿或严重呼吸困难的病人，考虑进行口咽或鼻咽插管以控制气道。使用带气囊的面罩进行正压通气技术可能有益。考虑使用药物治疗肺水肿……。对于严重的支气管痉挛，考虑给予β激动剂，如沙丁胺醇……。监测心率和必要时治疗心律失常……。开始静脉输注5%葡萄糖水（D5W），保持通路开放，最低流量/ SRP: "To keep open", minimal flow rate /. 如果出现低血容量的迹象，使用0.9%生理盐水（NS）或乳酸钠林格液（LR）。对于伴有低血容量迹象的低血压，谨慎给予液体。注意液体过载的迹象……。用安定（地西泮）或劳拉西泮（阿蒂万）治疗癫痫……。使用丙美卡因氢氯化物协助眼部冲洗……。/毒素A和B/

/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W TKO /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's (LR) if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam (Valium) or lorazepam (Ativan) ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

来源:Hazardous Substances Data Bank (HSDB)

安全信息

• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  4-氯吡啶 在 正丁基锂 、 六氯乙烷 作用下， 以 正己烷 、 四氢呋喃 为溶剂， 反应 2.0h， 以44%的产率得到2,4-二氯吡啶
  参考文献：
  名称：

  3-和4-氯吡啶的首次区域选择性C-2锂化

  摘要：

  我们已经证明 BuLi/LiDMAE 试剂促进了 3- 和 4- 氯吡啶的清洁和区域选择性 C2 锂化，而其他试剂如 LDA 或 BuLi/TMEDA 导致经典的邻位锂化产物或区域异构体的混合物。该方法已成功应用于各种活性2,3-和2,4-二取代吡啶的制备。

  DOI：

  10.1002/1099-0690(200102)2001:3<603::aid-ejoc603>3.0.co;2-2
• 作为产物：
  描述：

  4-氨基吡啶 在 亚硝酸特丁酯 、 copper dichloride 作用下， 以 乙腈 、 乙二醇 为溶剂， 以47%的产率得到4-氯吡啶
  参考文献：
  名称：

  沙梅尔反应从间歇到连续过程的高效换位

  摘要：

  研究了桑德迈尔氯化法从批次到安全连续流过程的转换。我们最初的方法是开发一种使用流化学的级联方法，该方法涉及重氮盐的生成并用氯化铜淬灭。为了实现这种安全的连续过程重氮化，使用了化学计量方法（Simplex方法）并外推以建立完全连续流方法。还通过合成几种（杂）芳基氯来检查反应范围。还对过程进行了验证和放大。在提高安全性的同时获得了更高的生产率。

  DOI：

  10.1021/acs.oprd.6b00318
• 作为试剂：
  描述：

  2-phenyl-5-methylene-4,5-dihydrooxazole 、 苯亚磺酸 在 4-氯吡啶 、 copper(l) iodide 作用下， 以 乙腈 为溶剂， 反应 5.0h， 以81%的产率得到2-phenyl-5-((phenylsulfonyl)methyl)oxazole
  参考文献：
  名称：

  Synergistic Gold and Iron Dual Catalysis: Preferred Radical Addition toward Vinyl–Gold Intermediate over Alkene

  摘要：

  A dual catalytic approach enlisting gold and iron, synergy is described. This method offers readily access to substituted heterocycle aldehydes via oxygen radical addition to vinyl-gold intermediates under Fe catalyst assistance. This system shows good functional group compatibility for the generation of substituted oxazole, indole, and benzofuran aldehydes. Mechanistic evidence greatly supports selective radical addition to an: activated vinyl-Au double bond over alkene. This unique discovery offers a new avenue with great potential to further extend the synthetic power and versatility of gold catalysis.

  DOI：

  10.1021/jacs.5b05415

文献信息

• [EN] ARYL ETHER-BASE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES DE TYPE ARYLÉTHER-BASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015038112A1

  公开（公告）日：2015-03-19

  The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

  本公开涉及一般可抑制AAK1（适配器相关激酶1）的化合物，包括这些化合物的组合物，以及抑制AAK1的方法。
• [EN] NEW COMPOUNDS II<br/>[FR] COMPOSÉS INÉDITS II
  申请人：BIOVITRUM AB PUBL

  公开号：WO2010031791A1

  公开（公告）日：2010-03-25

  The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as such as inflammatory diseases and immune disorders.

  本发明涉及式(I)的化合物及其药学上可接受的盐、溶剂合物、水合物、几何异构体、互变异构体、光学异构体或N-氧化物，这些化合物是SSAO活性的抑制剂。该发明还涉及包含这些化合物的药物组合物，以及利用这些化合物治疗抑制SSAO活性有益的医疗状况，例如炎症性疾病和免疫紊乱。
• [EN] SULFONYLATED TETRAHYDROAZOLOPYRAZINES AND THEIR USE AS MEDICINAL PRODUCTS<br/>[FR] TÉTRAHYDROAZOLOPYRAZINES SULFONYLÉES ET LEUR UTILISATION EN TANT QUE PRODUITS MÉDICAMENTEUX
  申请人：GRUENENTHAL GMBH

  公开号：WO2010099938A1

  公开（公告）日：2010-09-10

  The present invention relates to sulfonylated tetrahydroazolopyrazines, methods for the preparation thereof, medicinal products containing these compounds and the use of substituted indole compounds for the preparation of medicinal products (Formula I).

  本发明涉及磺酰化四氢咯啉吡嗪，其制备方法，含有这些化合物的药物产品以及用于制备药物产品的取代吲哚化合物的使用（式I）。
• HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Asana Biosciences, LLC

  公开号：US20160362407A1

  公开（公告）日：2016-12-15

  The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R 1 to R 8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.

  本申请提供了新颖的杂环化合物及其药用可接受的盐。还提供了制备这些化合物的方法。这些化合物对抑制ERK1/2有用。通过向需要治疗的患者施用式(I)的一个或多个化合物的治疗有效量，其中X、Y、Z、J、M和R1至R8在此处定义，这些化合物在治疗与RAS/RAF/MEK/ERK通路失调相关的疾病方面是有效的。可以使用这些化合物治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。
• [EN] CATALYST COMPLEXES WITH CARBENE LIGAND AND METHOD FOR MAKING SAME AND USE IN METATHESIS REACTION<br/>[FR] COMPLEXES DE CATALYSEURS AVEC UN LIGAND CARBÈNE, LEUR PROCÉDÉ DE FABRICATION ET LEUR UTILISATION DANS UNE RÉACTION DE MÉTATHÈSE
  申请人：GUANG MING INNOVATION COMPANY WUHAN

  公开号：WO2014108071A1

  公开（公告）日：2014-07-17

  This invention relates to catalyst compounds and the synthesis and applications useful in olefin metathesis reactions. The catalyst compounds of the invention are represented by the formula (I): wherein M is a Group 8 metal; X1 and X2 are anionic ligands; L1 and L2 are neutral two electron donor ligands. The present invention also relates to an easy applicable catalyst synthesis and the application in different olefin metathesis processes, e.g. Reaction Injection Molding (RIM), process to make α-olefins from fatty acid ester, e.g. methyl oleate.

  这项发明涉及催化剂化合物，以及在烯烃转化反应中有用的合成和应用。该发明的催化剂化合物由式(I)表示：其中M是8族金属；X1和X2是阴离子配体；L1和L2是中性的双电子给体配体。本发明还涉及一种易于应用的催化剂合成方法，以及在不同烯烃转化过程中的应用，例如反应注射成型（RIM）过程，用于从脂肪酸酯制备α-烯烃，例如甲基油酸甲酯。

表征谱图